T1	CHEM 3 10	TYSABRI
#1	AnnotatorNotes T1	C1529600
T2	PROC 36 59	perfusion intraveineuse
#2	AnnotatorNotes T2	C0455142
T3	CHEM 95 102	TYSABRI
#3	AnnotatorNotes T3	C1529600
T4	LIVB 135 141	sujets
#4	AnnotatorNotes T4	C0027361
T5	LIVB 212 222	population
#5	AnnotatorNotes T5	C0242445
T6	CHEM 227 234	TYSABRI
#6	AnnotatorNotes T6	C1529600
T7	LIVB 263 270	enfants
#7	AnnotatorNotes T7	C0008059
T8	LIVB 278 289	adolescents
#8	AnnotatorNotes T8	C0205653
T9	PROC 324 329	étude
#9	AnnotatorNotes T9	C2603343
T10	DISO 383 402	insuffisance rénale
#10	AnnotatorNotes T10	C1565489
T11	ANAT 396 402	rénale
#11	AnnotatorNotes T11	C0022646
T12	DISO 406 415	hépatique
#12	AnnotatorNotes T12	C1306571
T13	ANAT 406 415	hépatique
#13	AnnotatorNotes T13	C0023884
T14	PROC 470 476	études
#14	AnnotatorNotes T14	C2603343
T15	DISO 590 609	insuffisance rénale
#15	AnnotatorNotes T15	C1565489
T16	ANAT 603 609	rénale
#16	AnnotatorNotes T16	C0022646
T17	DISO 613 622	hépatique
#17	AnnotatorNotes T17	C1306571
T18	ANAT 613 622	hépatique
#18	AnnotatorNotes T18	C0023884
T19	PHEN 712 718	emploi
#19	AnnotatorNotes T19	C0014007
T20	DISO 743 759	Hypersensibilité
#20	AnnotatorNotes T20	C0020517
T21	CHEM 763 774	natalizumab
#21	AnnotatorNotes T21	C1172734
T22	CHEM 791 801	excipients
#22	AnnotatorNotes T22	C0015237
T23	DISO 806 850	Leucoencéphalopathie multifocale progressive
#23	AnnotatorNotes T23	C0023524
T24	DISO 853 857	LEMP
#24	AnnotatorNotes T24	C0023524
T25	LIVB 863 871	Patients
#25	AnnotatorNotes T25	C0030705
T26	DISO 903 927	infections opportunistes
#26	AnnotatorNotes T26	C0029118
T27	LIVB 940 948	patients
#27	AnnotatorNotes T27	C0030705
T28	LIVB 966 974	patients
#28	AnnotatorNotes T28	C0030705
T29	PROC 980 990	traitement
#29	AnnotatorNotes T29	C0087111
T30	LIVB 1012 1020	patients
#30	AnnotatorNotes T30	C0030705
T31	PROC 1044 1054	traitement
#31	AnnotatorNotes T31	C0087111
T32	CHEM 1082 1094	mitoxantrone
#32	AnnotatorNotes T32	C0026259
T33	CHEM 1098 1114	cyclophosphamide
#33	AnnotatorNotes T33	C0010583
T34	PHYS 1166 1177	Association
#34	AnnotatorNotes T34	C0004083
T35	CHEM 1187 1203	interférons bêta
#35	AnnotatorNotes T35	C0015980
T36	CHEM 1211 1233	acétate de glatiramère
#36	AnnotatorNotes T36	C0289884
T37	CHEM 1211 1218	acétate
#37	AnnotatorNotes T37	C0000975
T38	DISO 1238 1245	Cancers
#38	AnnotatorNotes T38	C0027651
T39	DISO 1295 1330	carcinomes cutanés baso-cellulaires
#39	AnnotatorNotes T39	C0007117
T40	DISO 1295 1305	carcinomes
#40	AnnotatorNotes T40	C0007097
T41	ANAT 1306 1313	cutanés
#41	AnnotatorNotes T41	C1123023
T42	DISO 1335 1379	Leucoencéphalopathie multifocale progressive
#42	AnnotatorNotes T42	C0023524
T43	DISO 1382 1386	LEMP
#43	AnnotatorNotes T43	C0023524
T44	PROC 1405 1438	imagerie par résonance magnétique
#44	AnnotatorNotes T44	C0024485
T45	PROC 1441 1444	IRM
#45	AnnotatorNotes T45	C0024485
T46	PROC 1564 1574	traitement
#46	AnnotatorNotes T46	C0087111
T47	CHEM 1579 1586	TYSABRI
#47	AnnotatorNotes T47	C1529600
T48	LIVB 1595 1603	patients
#48	AnnotatorNotes T48	C0030705
T49	DISO 1708 1717	symptômes
#49	AnnotatorNotes T49	C1457887
T50	DISO 1724 1744	signes neurologiques
#50	AnnotatorNotes T50	C0751378
T51	DISO 1765 1769	LEMP
#51	AnnotatorNotes T51	C0023524
T52	LIVB 1777 1784	médecin
#52	AnnotatorNotes T52	C0031831
T53	LIVB 1817 1824	patient
#53	AnnotatorNotes T53	C0030705
T54	DISO 1848 1857	symptômes
#54	AnnotatorNotes T54	C1457887
T55	DISO 1871 1901	dysfonctionnement neurologique
#55	AnnotatorNotes T55	C0751377
T56	DISO 1949 1958	symptômes
#56	AnnotatorNotes T56	C1457887
T57	DISO 1981 1984	SEP
#57	AnnotatorNotes T57	C0026769
T58	DISO 2007 2011	LEMP
#58	AnnotatorNotes T58	C0023524
T59	PROC 2078 2081	IRM
#59	AnnotatorNotes T59	C0024485
T60	CHEM 2103 2123	produit de contraste
#60	AnnotatorNotes T60	C0009924
T61	PROC 2146 2149	IRM
#61	AnnotatorNotes T61	C0024485
T62	PROC 2165 2175	traitement
#62	AnnotatorNotes T62	C0087111
T63	ANAT 2198 2201	ADN
#63	AnnotatorNotes T63	C0012854
T64	LIVB 2205 2213	virus JC
#64	AnnotatorNotes T64	C0022369
T65	LIVB 2205 2210	virus
#65	AnnotatorNotes T65	C0042776
T66	CHEM 2222 2225	LCR
#66	AnnotatorNotes T66	C0007806
T67	ANAT 2222 2225	LCR
#67	AnnotatorNotes T67	C0007806
T68	PROC 2240 2261	examens neurologiques
#68	AnnotatorNotes T68	C0027853
T69	LIVB 2370 2378	patients
#69	AnnotatorNotes T69	C0030705
T70	DISO 2394 2413	sclérose en plaques
#70	AnnotatorNotes T70	C0026769
T71	PROC 2417 2424	traités
#71	AnnotatorNotes T71	C0087111
T72	CHEM 2429 2436	TYSABRI
#72	AnnotatorNotes T72	C1529600
T73	PROC 2471 2481	traitement
#73	AnnotatorNotes T73	C0087111
T74	CHEM 2486 2497	natalizumab
#74	AnnotatorNotes T74	C1172734
T75	DISO 2557 2561	LEMP
#75	AnnotatorNotes T75	C0023524
T76	DISO 2602 2619	examens cliniques
#76	AnnotatorNotes T76	C1456356
T77	PROC 2626 2634	imagerie
#77	AnnotatorNotes T77	C0011923
T78	PROC 2643 2654	biologiques
#78	AnnotatorNotes T78	C0525044
T79	LIVB 2693 2700	médecin
#79	AnnotatorNotes T79	C0031831
T80	DISO 2758 2767	symptômes
#80	AnnotatorNotes T80	C1457887
T81	DISO 2787 2791	LEMP
#81	AnnotatorNotes T81	C0023524
T82	LIVB 2799 2806	patient
#82	AnnotatorNotes T82	C0030705
T83	DISO 2849 2886	symptômes cognitifs ou psychiatriques
#83	AnnotatorNotes T83	C0525041
T84	DISO 2849 2858	symptômes
#84	AnnotatorNotes T84	C1457887
T85	DISO 2922 2926	LEMP
#85	AnnotatorNotes T85	C0023524
T86	PROC 2932 2942	traitement
#86	AnnotatorNotes T86	C0087111
T87	CHEM 2947 2954	TYSABRI
#87	AnnotatorNotes T87	C1529600
T88	ANAT 3016 3035	système immunitaire
#88	AnnotatorNotes T88	C0020962
T89	LIVB 3045 3053	patients
#89	AnnotatorNotes T89	C0030705
T90	DISO 3079 3083	LEMP
#90	AnnotatorNotes T90	C0023524
T91	DISO 3241 3245	LEMP
#91	AnnotatorNotes T91	C0023524
T92	DISO 3253 3272	arrêt du traitement
#92	AnnotatorNotes T92	C1699848
T93	PROC 3262 3272	traitement
#93	AnnotatorNotes T93	C0087111
T94	CHEM 3277 3284	TYSABRI
#94	AnnotatorNotes T94	C1529600
T95	DISO 3372 3396	infections opportunistes
#95	AnnotatorNotes T95	C0029118
T96	DISO 3372 3382	infections
#96	AnnotatorNotes T96	C0021311
T97	DISO 3403 3427	infections opportunistes
#97	AnnotatorNotes T97	C0029118
T98	DISO 3403 3413	infections
#98	AnnotatorNotes T98	C0021311
T99	LIVB 3464 3472	patients
#99	AnnotatorNotes T99	C0030705
T100	DISO 3473 3482	souffrant
#100	AnnotatorNotes T100	C0857256
T101	DISO 3486 3489	SEP
#101	AnnotatorNotes T101	C0026769
T102	PROC 3493 3500	traités
#102	AnnotatorNotes T102	C0087111
T103	CHEM 3505 3512	TYSABRI
#103	AnnotatorNotes T103	C1529600
T104	DISO 3580 3602	infection opportuniste
#104	AnnotatorNotes T104	C0029118
T105	DISO 3580 3589	infection
#105	AnnotatorNotes T105	C0021311
T106	PROC 3608 3618	traitement
#106	AnnotatorNotes T106	C0087111
T107	CHEM 3623 3630	TYSABRI
#107	AnnotatorNotes T107	C1529600
T108	DISO 3694 3703	infection
#108	AnnotatorNotes T108	C0021311
T109	PROC 3731 3738	examens
#109	AnnotatorNotes T109	C0582103
T110	DISO 3779 3801	infection opportuniste
#110	AnnotatorNotes T110	C0029118
T111	DISO 3779 3788	infection
#111	AnnotatorNotes T111	C0021311
T112	CHEM 3807 3814	TYSABRI
#112	AnnotatorNotes T112	C1529600
T113	PROC 3854 3864	traitement
#113	AnnotatorNotes T113	C0087111
T114	LIVB 3880 3888	médecins
#114	AnnotatorNotes T114	C0031831
T115	CHEM 3922 3929	TYSABRI
#115	AnnotatorNotes T115	C1529600
T116	LIVB 4015 4023	patients
#116	AnnotatorNotes T116	C0030705
T117	DISO 4039 4058	sclérose en plaques
#117	AnnotatorNotes T117	C0026769
T118	PROC 4062 4069	traités
#118	AnnotatorNotes T118	C0087111
T119	CHEM 4074 4081	TYSABRI
#119	AnnotatorNotes T119	C1529600
T120	LIVB 4090 4098	patients
#120	AnnotatorNotes T120	C0030705
T121	DISO 4167 4176	infection
#121	AnnotatorNotes T121	C0021311
T122	LIVB 4205 4212	médecin
#122	AnnotatorNotes T122	C0031831
T123	PROC 4227 4234	traités
#123	AnnotatorNotes T123	C0087111
T124	CHEM 4239 4246	TYSABRI
#124	AnnotatorNotes T124	C1529600
T125	LIVB 4255 4263	médecins
#125	AnnotatorNotes T125	C0031831
T126	LIVB 4285 4293	patients
#126	AnnotatorNotes T126	C0030705
T127	PROC 4337 4347	traitement
#127	AnnotatorNotes T127	C0087111
T128	PROC 4393 4403	traitement
#128	AnnotatorNotes T128	C0087111
T129	DISO 4420 4436	Hypersensibilité
#129	AnnotatorNotes T129	C0020517
T130	DISO 4460 4476	hypersensibilité
#130	AnnotatorNotes T130	C0020517
T131	CHEM 4516 4523	TYSABRI
#131	AnnotatorNotes T131	C1529600
T132	PHYS 4549 4570	réactions systémiques
#132	AnnotatorNotes T132	C1710276
T133	PROC 4655 4664	perfusion
#133	AnnotatorNotes T133	C0031001
T134	PROC 4705 4714	perfusion
#134	AnnotatorNotes T134	C0031001
T135	DISO 4746 4762	hypersensibilité
#135	AnnotatorNotes T135	C0020517
T136	PROC 4807 4817	perfusions
#136	AnnotatorNotes T136	C0031001
T137	LIVB 4837 4845	patients
#137	AnnotatorNotes T137	C0030705
T138	CHEM 4866 4873	TYSABRI
#138	AnnotatorNotes T138	C1529600
T139	DISO 4884 4894	exposition
#139	AnnotatorNotes T139	C2905623
T140	PROC 4925 4935	perfusions
#140	AnnotatorNotes T140	C0031001
T141	PROC 4976 4986	traitement
#141	AnnotatorNotes T141	C0087111
T142	DISO 5050 5066	hypersensibilité
#142	AnnotatorNotes T142	C0020517
T143	PROC 5095 5104	perfusion
#143	AnnotatorNotes T143	C0031001
T144	DISO 5183 5199	hypersensibilité
#144	AnnotatorNotes T144	C0020517
T145	PROC 5229 5239	traitement
#145	AnnotatorNotes T145	C0087111
T146	CHEM 5244 5251	TYSABRI
#146	AnnotatorNotes T146	C1529600
T147	PROC 5280 5290	traitement
#147	AnnotatorNotes T147	C0087111
T148	DISO 5338 5344	signes
#148	AnnotatorNotes T148	C0037088
T149	DISO 5348 5357	symptômes
#149	AnnotatorNotes T149	C1457887
T150	DISO 5362 5378	hypersensibilité
#150	AnnotatorNotes T150	C0020517
T151	LIVB 5387 5395	patients
#151	AnnotatorNotes T151	C0030705
T152	DISO 5428 5444	hypersensibilité
#152	AnnotatorNotes T152	C0020517
T153	PROC 5479 5489	traitement
#153	AnnotatorNotes T153	C0087111
T154	CHEM 5494 5501	TYSABRI
#154	AnnotatorNotes T154	C1529600
T155	PROC 5506 5516	Traitement
#155	AnnotatorNotes T155	C0087111
T156	PROC 5528 5538	traitement
#156	AnnotatorNotes T156	C0087111
T157	CHEM 5553 5571	immunosuppresseurs
#157	AnnotatorNotes T157	C0021081
T158	CHEM 5608 5615	TYSABRI
#158	AnnotatorNotes T158	C1529600
T159	PROC 5644 5655	traitements
#159	AnnotatorNotes T159	C0087111
T160	CHEM 5656 5674	immunosuppresseurs
#160	AnnotatorNotes T160	C0021081
T161	CHEM 5678 5691	anticancéreux
#161	AnnotatorNotes T161	C0003392
T162	CHEM 5768 5779	médicaments
#162	AnnotatorNotes T162	C0013227
T163	CHEM 5785 5792	TYSABRI
#163	AnnotatorNotes T163	C1529600
T164	DISO 5834 5844	infections
#164	AnnotatorNotes T164	C0021311
T165	DISO 5861 5885	infections opportunistes
#165	AnnotatorNotes T165	C0029118
T166	DISO 5861 5871	infections
#166	AnnotatorNotes T166	C0021311
T167	LIVB 5957 5965	patients
#167	AnnotatorNotes T167	C0030705
T168	PROC 5980 5990	traitement
#168	AnnotatorNotes T168	C0087111
T169	CHEM 6005 6023	immunosuppresseurs
#169	AnnotatorNotes T169	C0021081
T170	CHEM 6033 6049	cyclophosphamide
#170	AnnotatorNotes T170	C0010583
T171	CHEM 6053 6065	mitoxantrone
#171	AnnotatorNotes T171	C0026259
T172	PHYS 6091 6108	immunosuppression
#172	AnnotatorNotes T172	C0021080
T173	DISO 6146 6150	LEMP
#173	AnnotatorNotes T173	C0023524
T174	LIVB 6164 6172	patients
#174	AnnotatorNotes T174	C0030705
T175	PROC 6187 6197	traitement
#175	AnnotatorNotes T175	C0087111
T176	CHEM 6212 6229	immunosuppresseur
#176	AnnotatorNotes T176	C0021081
T177	ANAT 6315 6334	système immunitaire
#177	AnnotatorNotes T177	C0020962
T178	PROC 6359 6369	traitement
#178	AnnotatorNotes T178	C0087111
T179	CHEM 6374 6381	TYSABRI
#179	AnnotatorNotes T179	C1529600
T180	LIVB 6388 6396	médecins
#180	AnnotatorNotes T180	C0031831
T181	PHYS 6480 6497	immunosuppression
#181	AnnotatorNotes T181	C0021080
T182	PROC 6538 6544	études
#182	AnnotatorNotes T182	C2603343
T183	DISO 6584 6587	SEP
#183	AnnotatorNotes T183	C0026769
T184	PROC 6593 6603	traitement
#184	AnnotatorNotes T184	C0087111
T185	CHEM 6637 6648	corticoïdes
#185	AnnotatorNotes T185	C0001617
T186	DISO 6725 6735	infections
#186	AnnotatorNotes T186	C0021311
T187	CHEM 6761 6772	corticoïdes
#187	AnnotatorNotes T187	C0001617
T188	CHEM 6819 6826	TYSABRI
#188	AnnotatorNotes T188	C1529600
T189	DISO 6835 6860	aggravation de la maladie
#189	AnnotatorNotes T189	C0242656
T190	DISO 6853 6860	maladie
#190	AnnotatorNotes T190	C0012634
T191	PROC 6901 6910	perfusion
#191	AnnotatorNotes T191	C0031001
T192	CHEM 6956 6965	anticorps
#192	AnnotatorNotes T192	C0003241
T193	CHEM 6973 6984	natalizumab
#193	AnnotatorNotes T193	C1172734
T194	LIVB 7012 7020	patients
#194	AnnotatorNotes T194	C0030705
T195	CHEM 7049 7058	anticorps
#195	AnnotatorNotes T195	C0003241
T196	PROC 7079 7089	traitement
#196	AnnotatorNotes T196	C0087111
T197	PROC 7182 7192	traitement
#197	AnnotatorNotes T197	C0087111
T198	DISO 7231 7250	troubles hépatiques
#198	AnnotatorNotes T198	C0023895
T199	ANAT 7240 7250	hépatiques
#199	AnnotatorNotes T199	C0023884
T200	CHEM 7321 7328	Tysabri
#200	AnnotatorNotes T200	C1529600
T201	DISO 7337 7356	troubles hépatiques
#201	AnnotatorNotes T201	C0086565
T202	ANAT 7346 7356	hépatiques
#202	AnnotatorNotes T202	C0023884
T203	PROC 7400 7410	traitement
#203	AnnotatorNotes T203	C0087111
T204	PROC 7436 7445	perfusion
#204	AnnotatorNotes T204	C0031001
T205	PHYS 7453 7482	fonction biologique hépatique
#205	AnnotatorNotes T205	C0232740
T206	ANAT 7473 7482	hépatique
#206	AnnotatorNotes T206	C0023884
T207	LIVB 7487 7495	patients
#207	AnnotatorNotes T207	C0030705
T208	PROC 7496 7503	traités
#208	AnnotatorNotes T208	C0087111
T209	LIVB 7551 7559	patients
#209	AnnotatorNotes T209	C0030705
T210	LIVB 7615 7622	médecin
#210	AnnotatorNotes T210	C0031831
T211	DISO 7645 7651	signes
#211	AnnotatorNotes T211	C0037088
T212	DISO 7655 7664	symptômes
#212	AnnotatorNotes T212	C1457887
T213	DISO 7679 7698	troubles hépatiques
#213	AnnotatorNotes T213	C0086565
T214	ANAT 7688 7698	hépatiques
#214	AnnotatorNotes T214	C0023884
T215	DISO 7719 7738	troubles hépatiques
#215	AnnotatorNotes T215	C0086565
T216	ANAT 7728 7738	hépatiques
#216	AnnotatorNotes T216	C0023884
T217	PROC 7758 7768	traitement
#217	AnnotatorNotes T217	C0087111
T218	CHEM 7773 7780	TYSABRI
#218	AnnotatorNotes T218	C1529600
T219	DISO 7803 7822	Arrêt du traitement
#219	AnnotatorNotes T219	C1699848
T220	PROC 7812 7822	traitement
#220	AnnotatorNotes T220	C0087111
T221	CHEM 7827 7834	TYSABRI
#221	AnnotatorNotes T221	C1529600
T222	DISO 7860 7879	arrêt du traitement
#222	AnnotatorNotes T222	C1699848
T223	PROC 7869 7879	traitement
#223	AnnotatorNotes T223	C0087111
T224	LIVB 7885 7892	médecin
#224	AnnotatorNotes T224	C0031831
T225	CHEM 7917 7928	natalizumab
#225	AnnotatorNotes T225	C1172734
T226	ANAT 7951 7955	sang
#226	AnnotatorNotes T226	C0005767
T227	ANAT 8024 8035	lymphocytes
#227	AnnotatorNotes T227	C0024264
T228	PROC 22 32	administré
#228	AnnotatorNotes T228	C3469597
T229	LIVB 135 164	sujets âgés de plus de 65 ans
#229	AnnotatorNotes T229	C0001792 C0001795
T231	PROC 2038 2061	examens complémentaires
#231	AnnotatorNotes T231	C1522577
T232	PROC 2350 2365	prise en charge
#232	AnnotatorNotes T232	C0030677
T233	DISO 3054 3068	immunodéprimés
#233	AnnotatorNotes T233	C1334159
T234	PROC 6786 6798	administrées
#234	AnnotatorNotes T234	C3469597
T235	CHEM 6956 6984	anticorps anti - natalizumab
#235	AnnotatorNotes T235	C1977362
T236	DISO 7758 7768;7781 7798	traitement devra être arrêté
#236	AnnotatorNotes T236	C1699848
T237	DISO 5453 5489	arrêter définitivement le traitement
#237	AnnotatorNotes T237	C1699848
T238	DISO 4322 4347	interrompre le traitement
#238	AnnotatorNotes T238	C1699848
T239	DISO 3835 3864	arrêt définitif du traitement
#239	AnnotatorNotes T239	C1699848
T240	DISO 2932 2942;2966 2987	traitement arrêté définitivement
#240	AnnotatorNotes T240	C1699848
T241	PROC 3995 4010	prise en charge
#241	AnnotatorNotes T241	C0030677
T242	PROC 5137 5152	prise en charge
#242	AnnotatorNotes T242	C0030677
T243	PROC 8084 8098	administration
#243	AnnotatorNotes T243	C3469597
